These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27069196)

  • 1. Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells.
    Čapoun O; Mikulová V; Jančíková M; Honová H; Kološtová K; Sobotka R; Michael P; Zima T; Hanuš T; Soukup V
    Anticancer Res; 2016 Apr; 36(4):2019-26. PubMed ID: 27069196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
    Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
    Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.
    Todenhöfer T; Hennenlotter J; Feyerabend S; Aufderklamm S; Mischinger J; Kühs U; Gerber V; Fetisch J; Schilling D; Hauch S; Stenzl A; Schwentner C
    Anticancer Res; 2012 Aug; 32(8):3507-13. PubMed ID: 22843938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
    Vogelzang NJ; Fizazi K; Burke JM; De Wit R; Bellmunt J; Hutson TE; Crane E; Berry WR; Doner K; Hainsworth JD; Wiechno PJ; Liu K; Waldman MF; Gandhi A; Barton D; Jungnelius U; Fandi A; Sternberg CN; Petrylak DP
    Eur Urol; 2017 Feb; 71(2):168-171. PubMed ID: 27522164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.
    Thalgott M; Heck MM; Eiber M; Souvatzoglou M; Hatzichristodoulou G; Kehl V; Krause BJ; Rack B; Retz M; Gschwend JE; Andergassen U; Nawroth R
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1457-64. PubMed ID: 25708944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
    Danila DC; Samoila A; Patel C; Schreiber N; Herkal A; Anand A; Bastos D; Heller G; Fleisher M; Scher HI
    Cancer J; 2016; 22(5):315-320. PubMed ID: 27749322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
    Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A
    Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
    Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
    Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
    Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
    Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.
    Strijbos MH; Gratama JW; Schmitz PI; Rao C; Onstenk W; Doyle GV; Miller MC; de Wit R; Terstappen LW; Sleijfer S
    Eur J Cancer; 2010 Jul; 46(11):2027-35. PubMed ID: 20399640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
    Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
    Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
    Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
    J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
    Du J; Yang Q; Chen XS; Tian J; Yao X
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.